Mitzie Hewitt, DO
Family Medicine · Buckley, MINPI 1861568479
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,130 of the $3,505 with a category attached, or 60.8%. Novo Nordisk accounts for 64.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $2,244, 2.9 times the $785 reported in 2019.
Across 57 payments — averaging $61.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Novo Nordisk AS$575
- AbbVie$102
- Sunovion Pharmaceuticals Inc.$98
- Astellas Pharma US Inc$87
- Progenacare Global, LLC$75
- plus $326 from 12 others
Across 1,883 payments — averaging $665.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$925K
- AstraZeneca$89K
- Kowa Research Institute, Inc.$79K
- Esperion Therapeutics, Inc.$49K
- Astrazeneca UK Limited$41K
- Genentech, Inc.$29K
- plus $42K from 3 others
What the payments were for
- Consulting fees$2,13061%
- Travel & lodging$2256%
- Food & beverage$1,15033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $2,242 |
| Novo Nordisk AS | 2 | $575 |
| AbbVie | 6 | $102 |
| Sunovion Pharmaceuticals Inc. | 12 | $98 |
| Astellas Pharma US Inc | 5 | $87 |
| Progenacare Global, LLC | 3 | $75 |
| Pfizer | 4 | $64 |
| BD | 1 | $51 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Indivior Inc. | 1 | $31 |
| GSK | 2 | $27 |
| Exact Sciences | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Bayer | 1 | $13 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$2,130
How this compares
$3,505 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $132,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $71,496 |
| EliquisApixaban | 57 | $66,362 |
| MounjaroTirzepatide | 43 | $44,181 |
| FarxigaDapagliflozin Propanediol | 35 | $40,592 |
| JardianceEmpagliflozin | 42 | $34,586 |
| TrulicityDulaglutide | 20 | $28,619 |
| MyrbetriqMirabegron | 36 | $27,770 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $12,859 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,749 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,019 |
| TradjentaLinagliptin | 15 | $7,814 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $6,667 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,607 |
| Omeprazole | 166 | $4,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,242 | $132,265112 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $27 | $80,96687 claims |
| PfizerEliquis | $64 | $66,36257 claims |
| AstraZenecaFarxiga | $13 | $40,59235 claims |
| Astellas Pharma US IncMyrbetriq | $87 | $27,77036 claims |
| AbbVieSynthroid | $102 | $1,24624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Buckley
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.